💊 Rapamycin Companion Animal Aging Trial Simulator

Dogs as a Naturally Occurring Model of Mammalian Aging

Dogs age faster than humans, compressing decades of aging into a few years.

• 10–13 yrs: Median lifespan (vs ~80 for humans)
• 30+: Breeds enrolled (purebred and mixed)
• 30,000+: Cohort size (DAP) (Dog Aging Project dogs)
• ~7:1: Aging rate ratio (dog years per human year)

Why compressed lifespans accelerate aging research

Short dog lifespans let scientists observe aging outcomes within a few years.

Genetic and phenotypic diversity across dog breeds

Breed diversity mirrors human genetic variation in aging and disease risk.

Companion Dogs Share Our Homes, Diet, and Microbiome

Pet dogs share household exposures with owners, boosting real-world relevance.

• Many: Shared exposures (diet, pollutants, activity)
• Longitudinal: Data collection (surveys plus vet records)
• Annual: Sample frequency (blood, urine, DNA)
• Nationwide: Enrollment scope (US-wide citizen science)

Shared environment reduces confounding variables

Living alongside owners controls for diet and environmental confounders naturally.

Citizen science and owner-participation trial model

Owners submit health records and samples, scaling the study affordably.

Randomized, Placebo-Controlled Low-Dose Rapamycin Dosing

A randomized placebo-controlled design tests low, intermittent rapamycin dosing safely.

• Low-dose: Dose regimen (intermittent weekly dosing)
• 2: Trial arms (placebo vs rapamycin)
• 36 mo: Planned duration (longitudinal follow-up)
• Routine: Safety monitoring (bloodwork each visit)

Dosing rationale for intermittent low-dose regimens

Low, intermittent dosing aims to limit side effects while targeting mTOR.

Randomization and blinding to reduce bias

Dogs are randomly assigned and owners remain blinded to the arm.

Tracking Cardiac Function and Cognitive Decline Over Time

Echocardiograms and cognitive tests track age-related decline across both arms.

• Biannual: Echo interval (cardiac function scans)
• CCDR scale: Cognitive test (owner-completed questionnaire)
• Healthspan: Primary endpoint (not just lifespan)
• Multiple: Biomarker panels (inflammation, frailty markers)

Cardiac endpoints and echocardiographic monitoring

Heart function is scanned regularly to catch early age-related change.

Cognitive endpoints and owner-reported decline scores

Cognitive dysfunction scores flag early behavioral signs of brain aging.

From Companion Dogs to Human Longevity Trials

Positive dog outcomes support designing future human longevity trials.

• High: Translational value (shared-environment species)
• Human trials: Next step (geroscience pipeline)
• Growing: Regulatory interest (aging biomarker discussions)
• Strong: Public engagement (owner and media interest)

Translational pipeline from canine to human trials

Dog trial results help justify and design human rapamycin studies.

Open questions before broader clinical translation

Optimal dosing and long-term safety in humans remain open questions.